Abexinostat

Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It is currently under development by Pharmacyclics and is in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well.

Abexinostat exerts its effect as a histone deacetylase inhibitor.